Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study. - Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V.; Antonini, Angelo; Bergmans, Bruno; Bergquist, Filip; Bouchard, Manon; Budur, Kumar; Carroll, Camille; Chaudhuri, K. Ray; Criswell, Susan R.; Danielsen, Erik H.; et al. (Neurology & Therapy, 2023)